Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancer

Ribociclib in Early Breast Cancer | NEJMПодробнее

Adding ribociclib to endocrine therapy shows an improvement in invasive DFS in HR+/HER2 BC patientsПодробнее

ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- early breast cancerПодробнее

Remaining questions on the use of frontline CDK4/6 inhibitors + endocrine therapyПодробнее

NATALEE: ribociclib + NSAI as adjuvant treatment in patients with HR+/HER2− early breast cancerПодробнее

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancerПодробнее

Dr. Tripathy on Frontline Endocrine Therapies in HR+ Breast CancerПодробнее

Role of endocrine therapy in early-stage HR-positive breast cancerПодробнее

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-WynneПодробнее

Ribociclib in adjuvant HR+ breast cancerПодробнее

FDA Approves Ribociclib (Kisqali) for Stage 2-3 HR+/HER2- Breast Cancer at Higher Risk of RecurrenceПодробнее

NATALEE: ribociclib and NSAI in HR+/HER2- early breast cancerПодробнее

Ribociclib plus endocrine therapy boosts survival of HR+/HER2- breast cancerПодробнее

Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancerПодробнее

Overall survival results from MONALEESA-2: Endocrine therapy and ribociclib in HR positive and H...Подробнее

Early Stage Breast Cancer | 2022 OneOncology ConferenceПодробнее

Abemaciclib With Endocrine as Frontline TherapyПодробнее

Inclusion criteria for NATALEE Trial - evaluating importance of ajuvant ribociclib #oncology #cancerПодробнее

Frontline Therapy in HR-Positive Breast CancerПодробнее